OnADose vs InjectorMate
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
OnADose
This educational tool assists US healthcare professionals with onabotulinumtoxinA dosing and reconstitution for conditions like chronic migraine, spasticity, and cervical dystonia. It provides important safety information and indications for approved uses.
- OnabotulinumtoxinA dosing guidance
- Reconstitution information
- Educational tool for healthcare professionals
- Information on chronic migraine
- Information on spasticity
- Information on cervical dystonia
- Important safety information
Read full descriptionHide full description
OnADose is an onabotulinumtoxinA dosing and reconstitution educational tool for spasticity, cervical dystonia, and chronic migraine. This app is intended for training use by US healthcare professionals ONLY. Patients should seek a doctor’s advice before making any medical decisions. OnabotulinumtoxinA Important Safety Information OnabotulinumtoxinA Indications Chronic Migraine -OnabotulinumtoxinA is indicated for the prophylaxis of headaches in adult patients with Chronic Migraine (≥ 15 days per month with headache lasting 4 hours a day or longer). Limitations of Use -Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies. Spasticity -OnabotulinumtoxinA is indicated for the treatment of spasticity in patients 2 years of age and older. Limitations of Use -OnabotulinumtoxinA has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture. Cervical Dystonia -OnabotulinumtoxinA is indicated for the treatment of adults with Cervical Dystonia to reduce the severity of abnormal head position and neck pain associated with Cervical Dystonia. IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of onabotulinumtoxinA and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses. Contraindications -Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation -Infection at the proposed injection site Warnings and Precautions -Spread of toxin effects; swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or swallowing difficulties occur -Potency Units of onabotulinumtoxinA are not interchangeable with other preparations of botulinum toxin products -Potential serious adverse reactions after onabotulinumtoxinA injections for unapproved uses -Concomitant neuromuscular disorder may exacerbate clinical effects of treatment -Use with caution in patients with compromised respiratory function -Bronchitis and upper respiratory tract infections in patients treated for spasticity Adverse Reactions The most common adverse reactions (≥5% and >placebo, if applicable) are: -Chronic Migraine: neck pain, headache -Adult Spasticity: pain in extremity -Pediatric Spasticity: upper respiratory tract infection -Cervical Dystonia: dysphagia, upper respiratory infection, neck pain, headache, increased cough, flu syndrome, back pain, rhinitis Drug Interactions -Patients receiving concomitant treatment of onabotulinumtoxinA and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of onabotulinumtoxinA may be potentiated Use in Specific Populations -Pregnancy: Based on animal data, may cause fetal harm Please see full Prescribing Information for onabotulinumtoxinA. Available at http://www.rxabbvie.com. Copyright ©2022 AbbVie. All rights reserved.
InjectorMate
This augmented reality application allows users to practice facial injection techniques on virtual patients. It offers various treatment patterns for common aesthetic concerns and serves as a training tool for both new and experienced professionals.
- Augmented reality injection practice
- Virtual patient simulation
- Multiple treatment patterns
- Training for aesthetic therapy
- Skill retraining for professionals
Read full descriptionHide full description
Practice different angles and approaches and on any patient you choose. Multiple different patterns of treatment provided: crow’s feet, forehead creases, frown lines. InjectorMate is the perfect training tool for entrants into the exciting new field of aesthetic therapy and is highly effective for retraining and practicing skills even for seasoned professionals. Designed and powered by MachineMedicine Technologies by clinicians and for clinician use. Disclaimer: this is a purely educational app providing an augmented reality injection experience. It is not for providing diagnosis or treatment and cannot be used as such. Please see your physician for any medical diagnoses or plans.
Screenshots
Verdict
The clearest difference is rating: OnADose at 5.0 against InjectorMate's 1.0. OnADose also leads on ratings volume (3 vs 1) and iOS requirement (11.0 vs 15). InjectorMate's advantage is update cadence (every 5 days vs every 8 months). On price, ads, in-app purchases and monetization model there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
OnADose holds the better App Store score, 5.0 against 1.0. Both are backed by a comparable volume of ratings — 3 and 1 respectively.
OnADose ships an update every 8 months, InjectorMate every 5 days. The most recent releases landed on June 11, 2026 and September 11, 2026 respectively.
| Parameter | OnADose | InjectorMate |
|---|---|---|
| Price | Free | Free |
| Rating | 5.0 (3 ratings) — better | 1.0 (1 ratings) |
| Positive reviews | — | 100.0% of reviews |
| Number of ratings | 3 — better | 1 |
| Update frequency | Every 8 months | Every 5 days — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 11.0 — better | 15 |
| Further details — not scored | ||
| Size | 44 MB | 19 MB |
| Age rating | 12+ | 4+ |
| Developer | AbbVie Inc | MACHINE MEDICINE TECHNOLOGIES LIMITED |
Customer experience
OnADose
InjectorMate
In-app purchases
OnADose
No in-app purchases
InjectorMate
No in-app purchases









